Latest news with #geneticdisorders
Yahoo
26-05-2025
- Business
- Yahoo
Asia-Pacific and Middle East NGS Market Research 2025-2035: Growing Prevalence of Non-Communicable Diseases, Advancement in the Performance of NGS Platforms
The Asia-Pacific and Middle East NGS market is witnessing substantial growth due to advances in NGS technology, rising genetic disorders and cancer cases, and expanding precision medicine applications. Key growth drivers include demand for personalized medicine, government initiatives, and innovation in sequencing platforms enhancing efficiency and cost-effectiveness. The market is dominated by countries like China, India, and Saudi Arabia, yet faces challenges such as high costs, data privacy issues, and a shortage of skilled professionals. Opportunities abound in rapidly developing economies, AI integration, and new NGS applications. Notable developments include new sequencing systems by PacBio and innovations by Illumina, emphasizing continuous industry advancements. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific and Middle East NGS Market: Focus on Offering, Platform, Throughput, Technology Type, Application, End User, and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to Asia-Pacific and Middle East Next-Generation Sequencing (NGS) market is experiencing significant growth, driven by rapid advancements in next-generation sequencing technologies, the rising prevalence of genetic disorders and cancer, and the expanding application of next-generation sequencing in precision medicine. The Asia-Pacific and Middle East NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the Asia-Pacific and Middle East NGS market analyzed and profiled in the study involve established and players that offer various kinds of NGS platforms, consumables, and services. Continuous innovations in next-generation sequencing platforms have enhanced efficiency, accuracy, and cost-effectiveness, making next-generation sequencing more accessible for both clinical diagnostics and research purposes. The increasing demand for next-generation sequencing in personalized medicine, particularly in oncology, reproductive health, and infectious disease diagnostics, is further fueling market expansion. Additionally, strong government initiatives, increased R&D investments, and strategic collaborations between biotech firms and healthcare providers are propelling the growth of next-generation sequencing in the region. Countries such as China, India, and Saudi Arabia are leading large-scale genomic projects to advance early disease detection and precision healthcare, further strengthening the Asia-Pacific and Middle East NGS market the strong growth potential of the next-generation sequencing market, several challenges persist. The high cost associated with next-generation sequencing platforms, consumables, and data analysis tools remains a major barrier, particularly in low-income regions. The shortage of skilled professionals proficient in bioinformatics and genomic data interpretation further hinders the widespread adoption of next-generation sequencing technologies. Moreover, concerns related to data privacy, security, and regulatory compliance create complexities in the implementation of next-generation sequencing across different countries. Additionally, variations in healthcare regulations and ethical concerns surrounding genomic data usage add to the market's constraints, making the adoption of next-generation sequencing more challenging in certain regions. This factor is posing a challenge for the Asia-Pacific and Middle East NGS the next-generation sequencing market in the Asia-Pacific and Middle East regions presents significant opportunities for expansion. Emerging economies with rapidly improving healthcare infrastructure are increasingly investing in next-generation sequencing research and clinical applications. The integration of artificial intelligence (AI) and cloud-based bioinformatics is revolutionizing genomic data analysis, making next-generation sequencing more efficient and accessible. Furthermore, the growing use of next-generation sequencing in non-invasive prenatal testing (NIPT) and infectious disease research offers new growth avenues for market players. As governments and private sector companies continue investing in genomic research, precision medicine, and clinical applications, the next-generation sequencing market in Asia-Pacific and the Middle East is poised for substantial expansion in the coming years. Market Dynamics The following are the drivers for the Asia-Pacific and Middle East NGS market: Increasing Adoption of NGS in Various Research and Diagnostics Fields Growing Prevalence of Non-Communicable Diseases Advancement in the Performance of NGS Platforms The market is expected to face some limitations as well due to the following challenges: Dearth of Skilled Professionals in Middle East Countries High Cost of Installation and Maintenance of the Equipment Reimbursement and Regulatory Policies of NGS Key Market Segmentation The Asia-Pacific and Middle East NGS market (by offerings) is expected to be dominated by the consumables segment. The Asia-Pacific and Middle East NGS market (by platform) is expected to be dominated by Illumina, Inc. The Asia-Pacific and Middle East NGS market (by throughput) is expected to be dominated by the high-throughput segment. The Asia-Pacific NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment. The Asia-Pacific NGS market (by application) is expected to be dominated by the translational research segment. The Asia-Pacific NGS market (by end user) is expected to be dominated by the academic and research insitutes segment. The Asia-Pacific NGS market (by country) is expected to be dominated by Japan and the Middle East NGS market (by country) is expected to be dominated by the U.A.E. Key Topics Covered:1. Asia-Pacific and Middle East NGS Market Overview1.1 Market Outlook1.1.1 Definitions1.1.2 Inclusion and Exclusion Criteria1.1.3 Market Size, 2024 - 2035, $Million1.1.4 Key Findings1.1.5 Market Growth Scenario1.1.5.1 Realistic Scenario1.1.5.2 Optimistic Scenario1.1.5.3 Pessimistic Scenario1.2 Industry Outlook1.2.1 NGS: Market Overview and Ecosystem1.2.2 Asia-Pacific and Middle East NGS: Overview1.2.3 Key Trends and Emerging Application of NGS in Asia-Pacific and Middle East1.2.4 Patent Analysis1.2.5 Pricing Analysis1.2.5.1 Instrument1.2.5.2 Consumables1.2.6 Supply Chain Analysis1.2.6.1 Key Entities in Supply Chain1.2.7 Regulatory Framework1.2.7.1 Asia-Pacific1.2.7.2 Middle East1.2.8 Genome Projects1.2.8.1 Asia-Pacific1.2.8.1.1 China1.2.8.1.2 Japan1.2.8.1.3 India1.2.8.1.4 South Korea1.2.8.1.5 Singapore1.2.8.1.6 Other Asian Countries1.2.8.2 Middle East1.2.8.2.1 UAE1.2.8.2.2 Qatar1.2.8.2.3 Saudi Arabia1.2.8.2.4 Kuwait1.2.8.2.5 Other Middle East Countries1.3 Market Dynamics1.3.1 Market Drivers1.3.1.1 Impact Analysis1.3.2 Market Restraints1.3.2.1 Impact Analysis1.3.3 Market Opportunities2. Asia-Pacific and Middle East NGS Market Analysis (By Offering), $Million, 2024-20352.1 Consumables2.1.1 Library Preparation and Reagents2.1.2 Sequencing Kits and Reagents2.1.3 Others2.2 Equipment2.3 Services2.3.1 Sequencing Services2.3.2 Data Management Services3. Asia-Pacific and Middle East NGS Market Analysis (By Workflow), $Million, 2024-20353.1 Sequencing3.2 Pre-Sequencing3.3 Data Analysis4. Asia-Pacific and Middle East NGS Market Analysis (By Platform), $Million, 2024-20354.1 Overview4.1.1 Asia-Pacific4.1.2 Middle East4.2 Illumina, Inc. (Asia-Pacific and Middle East)4.3 Thermo Fisher Scientific, Inc. (Asia-Pacific and Middle East)4.4 Pacific Biosciences of California, Inc. (Asia-Pacific and Middle East)4.5 Oxford Nanopore Technologies plc. (Asia-Pacific and Middle East)4.6 Other Companies (Asia-Pacific and Middle East)5. Asia-Pacific and Middle East NGS Market Analysis (By Throughput), $Million, 2024-20355.1 Overview5.1.1 Asia-Pacific5.1.2 Middle East5.2 High-Throughput5.3 Medium-Throughput5.4 Low-Throughput6. Asia-Pacific and Middle East NGS Market Analysis (By Technology Type), $Million, 2024-20356.1 Sequencing by Synthesis6.2 Ion Torrent Semiconductor Sequencing6.3 Single Molecule Real-time Sequencing6.4 Nanopore Sequencing Technologies6.5 Other Technologies7. Asia-Pacific and Middle East NGS Market Analysis (By Application), $Million, 2024-20357.1 Clinical Diagnostics7.1.1 Oncology7.1.2 Infectious Diseases7.1.3 Reproductive Genetics7.1.4 Others7.2 Translational Research7.2.1 Clinical7.2.2 Agricultural7.2.3 Others8. Asia-Pacific and Middle East NGS Market Analysis (By End User), $Million, 2024-20358.1 Pharmaceutical and Biotechnology Companies8.2 Academic and Research Institution8.3 Clinical Laboratories8.4 Others9. Asia-Pacific NGS Market Analysis (By Country), $Million, 2024-20359.1 Market Overview9.2 Market Sizing and Forecast9.2.1 Japan9.2.2 China9.2.3 India9.2.4 South Korea9.2.5 Australia9.2.6 Singapore9.2.7 New Zealand9.2.8 Rest of Asia-Pacific10. Middle East NGS Market Analysis (By Country), $ Million, 2024-203510.1 Market Overview10.2 Market Sizing and Forecast10.2.1 UAE10.2.2 KSA10.2.3 Israel10.2.4 Egypt10.2.5 Rest-of-Middle East11. Asia-Pacific and Middle East NGS Market - Competitive Benchmarking and Company Profiles11.1 Competitive Benchmarking11.2 Competitive Landscape11.2.1 Key Strategies and Developments by Company11.2.1.1 Funding Activities11.2.1.2 Mergers and Acquisitions11.2.1.3 Regulatory Approvals11.2.1.4 Partnerships, Collaborations, and Business Expansions11.2.2 Market Share Analysis, 2024-203511.2.3 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by End User)11.2.4 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by Throughput)11.3 Company Profiles11.4 Emerging Companies (Asia-Pacific and Middle East)Companies Featured BGI Group Illumina, Inc. Thermo Fisher Scientific Inc. Pacific Biosciences of California, Inc. Oxford Nanopore Technologies plc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Guardian
23-05-2025
- Health
- The Guardian
Blood test developed that could speed up diagnosis of rare diseases in babies
A new blood-based test that could help speed up diagnoses for children born with rare genetic disorders has been developed by researchers in an effort to provide answers – and treatments – sooner. Rare genetic disorders include a host of conditions, from cystic fibrosis to diseases relating to the mitochondria – the powerhouses of our cells. However, getting a diagnosis can be arduous. 'In most cases people suspected of a rare disease undergo genomic testing, which revolutionised their diagnosis, but typically only leads to a diagnosis about 50% of the time,' said Dr David Stroud, the co-author of the study from the University of Melbourne. 'Those that don't receive a diagnosis from genomic testing often undergo a long 'diagnostic odyssey' of months to years where they undergo myriad other tests in an effort to interpret which of the many genetic changes detected in genomic testing are causing the disease,' he added. 'Some of these tests are very invasive, needing for example muscle biopsies, which in children requires general aesthetic, which has its own risks.' Writing in the journal Genome Medicine, Stroud and colleagues report how they sought to supplement genetic testing with another approach: examining the myriad proteins found within certain types of blood cells taken from a patient, and comparing them against those found in healthy people. 'Since genes are the instructions to make proteins, we then use this information to understand which of the thousands of changes in many different genes detected in a patient are leading to a damaged protein and which are benign,' said Stroud. The team say the approach means the effects of many different genetic mutations can be analysed at once and yield results in as little as three days. Among other results the researchers found the new approach outperformed current gold-standard tests for mitochondrial diseases that are used alongside genetic testing, and enabled the diagnosis of diseases where genomic testing alone had been unable to do so. 'Genomics is the frontline test and it can solve the diagnosis in about 30-50% of patients suspected of a rare disease. We think a single proteomic test can increase that diagnostic yield to 50-70% of suspected patients,' said Prof David Thorburn, another author of the research from the University of Melbourne. While the study focuses on using the test for mitochondrial diseases, Stroud said it was already applicable to about half of the 7,000 known rare diseases, although more work is needed to demonstrate this. Stroud added that for mitochondrial diseases as little as 1ml of blood from a newborn is required for the procedure, whereas current techniques involve a muscle biopsy. Furthermore, while a mitochondria-focused version of the test has a similar cost to current techniques, it is not specific to one kind of rare disease. That not only makes it more cost effective but, as Stroud noted, it also means patients could avoid having to take other unnecessary tests. 'This has obvious benefits to both the patient and healthcare system,' he said. A diagnosis not only sheds light on the disease, and – in some cases – possible treatments. It also helps parents who are considering having further children by raising the possibility of pre-natal genetic testing. Michal Minczuk, a professor of mitochondrial genetics, at the University of Cambridge, and who was not involved in the study, welcomed the research. 'Overall, the paper marks a very significant step forward in diagnostic practices by introducing a robust, rapid, and minimally invasive method for confirming and characterising genetic disorders,' he said. 'This could greatly enhance patient care by expanding the tools available for clinicians and researchers in genomic medicine.'
Yahoo
23-05-2025
- Business
- Yahoo
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche's SBX sequencing technology1, with an initial focus on critically ill newborns and their parents. Whole genome sequencing can help diagnose babies with suspected genetic disorders, such as cystic fibrosis and sickle cell disease. This project will explore how this technology could become part of routine clinical practice for newborns, as well as its use in other research applications. Basel, 23 May 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche's recently unveiled next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology. This collaboration will focus on harnessing the power of the SBX technology to transform clinical genomics and biomedical discovery. It will also aim to establish the SBX technology as a routine offering for fast, scalable sequencing for Broad Clinical Lab's research community. The first project will see Broad Clinical Labs using the SBX technology to advance research into trio-based whole genome sequencing of critically ill newborns and their biological parents. This program aims to establish a future state where whole genome sequencing becomes a routine component of clinical care in neonatal intensive care units (NICUs) —enabling precise, timely diagnoses and improved outcomes for infants with suspected genetic disorders. 'The SBX technology was designed with both clinical impact and scientific discovery in mind, and offers the next-generation of fast, scalable sequencing solutions,' said Matt Sause, CEO of Roche Diagnostics. 'Collaborating with Broad Clinical Labs, a leader in clinical genomics and omics research, accelerates our ability to deliver on that promise and support better outcomes for patients through cutting-edge genomic technology.' 'Integrating the SBX technology into clinical and translational pipelines opens exciting new possibilities,' said Niall Lennon, Chair and CSO at Broad Clinical Labs. 'Together with Roche, we're aiming to demonstrate how fast, scalable, and high-quality sequencing can support both routine clinical care and drive biomedical innovation.' The SBX technology represents a significant leap forward in next-generation sequencing, offering ultra-fast turnaround times, exceptional scalability, and cost efficiency across a range of sequencing applications. The SBX technology has been tailored to deliver high-throughput performance with a flexible workflow that will support rapid deployment in time-sensitive settings like neonatal intensive care units (NICUs) and comprehensive multi-omic discovery research. The collaboration will also explore the capabilities of the SBX technology for RNA sequencing, including both bulk and single-cell approaches. These efforts will focus on leveraging the longer reads of the SBX technology to unlock novel molecular insights and data types that could reshape how researchers understand disease mechanisms and identify new therapeutic targets. Broad Clinical Labs is a wholly owned subsidiary of the Broad Institute of MIT and Harvard. Broad Institute researchers, who have led the field in the development and application of single cell methods across a range of biomedical areas, will be the early users to leverage the new system. The collaboration between Roche and Broad Clinical Labs reflects a shared vision of a genomics-enabled healthcare system and reinforces both organizations' commitment to advancing precision medicine at scale. About Sequencing by Expansion (SBX) technologyRoche's groundbreaking next-generation sequencing technology is designed to overcome the limitations of traditional sequencing methods. As well as high accuracy, it also offers an unparalleled combination of flexibility and speed, making it a versatile tool for a wide range of genomic applications. One of the key benefits of the SBX technology is its scalability. The chemistry is coupled with an advanced, high-throughput CMOS sensor module that enables ultra-rapid, real-time base calls and analysis. This module is designed to process numerous samples simultaneously, creating a highly scalable and flexible architecture for cost-efficient sequencing across different project sizes, from small-scale studies to large projects involving thousands of samples. This versatility makes the SBX technology suitable for a variety of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. As a result, it holds promise not only for research laboratories but also eventually for clinical settings where detailed genomic insights are crucial. With SBX technology, researchers can meet new and evolving research demands efficiently, paving the way for significant advances in our understanding of genetics and disease, ultimately contributing to better healthcare outcomes. The SBX chemistry was invented by Mark Kokoris and Robert McRuer who co-founded Stratos Genomics. Stratos Genomics was acquired by Roche in 2020. To find out more about Roche's novel SBX technology, click here. About Broad Clinical LabsBroad Clinical Laboratories was founded in 2013 as a subsidiary of Broad Institute, Inc. to accelerate the world toward a better understanding, diagnosis, and treatment of disease by pursuing projects, developing products, and driving adoption of cutting edge -omics technologies and novel molecular assays. Broad Clinical Labs is a leader in human whole genome sequencing, having sequenced over 750,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease. For more information, please visit About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by The SBX technology is in development and not commercially available. The content of this material reflects current study results or design goals. Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Nina MählitzPhone: +41 79 327 54 74 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment 23052025_SBX Broad Clinical Labs_enError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
09-05-2025
- Health
- Yahoo
$9.48 Bn Medical Foods for Inborn Errors of Metabolism Market Opportunities and Strategies to 2034
Global Medical Foods Market for Inborn Errors of Metabolism to Surge by 78%: North America Leads, Asia Pacific Rising Fast Medical Foods for Inborn Errors of Metabolism Market Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Medical Foods for Inborn Errors of Metabolism Market Opportunities and Strategies to 2034" has been added to offering. This report describes and explains the Medical Foods for Inborn Errors of Metabolism market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region. The global Medical Foods for Inborn Errors of Metabolism market reached a value of nearly $3.07 billion in 2024, having grown at a compound annual growth rate (CAGR) of 9.94% since 2019. The market is expected to grow from $3.07 billion in 2024 to $5.5 billion in 2029 at a rate of 12.34%. The market is then expected to grow at a CAGR of 11.50% from 2029 and reach $9.48 billion in 2034. Growth in the historic period resulted from the rising detection of genetic disorders, expanding patient access to healthcare services, expanding healthcare infrastructure, and growth in healthcare expenditure globally. Factors that negatively affected growth in the historic period included the high cost of medical foods. Going forward, an increasing aging population, rising detection of inborn errors of metabolism, increasing focus on personalized nutrition, growing awareness and detection of metabolic disorders, and supportive government healthcare initiatives will drive the growth. Factors that could hinder the growth of the Medical Foods for Inborn Errors of Metabolism market in the future include regulatory classification confusion. The global Medical Foods for Inborn Errors of Metabolism market is fairly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up 21.88% of the total market in 2023. Fresenius Kabi was the largest competitor with a 3.21% share of the market, followed by Nestle S.A. with 3.18%, Abbott Laboratories Inc. with 3.00%, Mount Sinai Health System Inc. with 2.98%, Danone SA with 2.72%, Ajinomoto Co. Inc. with 2.17%, Reckitt Benckiser Group plc (Mead Johnson & Company, LLC) with 1.91%, Galen Limited with 1.36%, BC Children's Hospital with 0.69%, and Metagenics Inc. with 0.65%. The Medical Foods for Inborn Errors of Metabolism market is segmented by product into amino acid-based medical foods, Glytactin with GMP amino acid-modified infant formula with iron, low-calcium/vitamin D-free infant formula with iron, low protein food, and other products. The amino acid-based medical foods market was the largest segment of the Medical Foods for Inborn Errors of Metabolism market segmented by product, accounting for 47.06% or $1.44 billion of the total in 2024. Going forward, the Glytactin with GMP amino acid-modified infant formula with iron segment is expected to be the fastest-growing segment in the Medical Foods for Inborn Errors of Metabolism market segmented by product, at a CAGR of 13.49% during 2024-2029. The Medical Foods for Inborn Errors of Metabolism market is segmented by forms into powder, liquids, gels, and other forms. The powder market was the largest segment of the Medical Foods for Inborn Errors of Metabolism market segmented by forms, accounting for 51.26% or $1.57 billion of the total in 2024. Going forward, the gels segment is expected to be the fastest growing segment in the Medical Foods for Inborn Errors of Metabolism market segmented by forms, at a CAGR of 13.92% during 2024-2029. The Medical Foods for Inborn Errors of Metabolism market is segmented by distribution channel into retail pharmacies, hospital pharmacies, drug stores, online pharmacies, and other distribution channels. The retail pharmacies market was the largest segment of the Medical Foods for Inborn Errors of Metabolism market segmented by distribution channel, accounting for 34.23% or $1.05 billion of the total in 2024. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the Medical Foods for Inborn Errors of Metabolism market segmented by distribution channel, at a CAGR of 14.22% during 2024-2029. The Medical Foods for Inborn Errors of Metabolism market is segmented by diseases into Phenylketonuria (PKU), organic acidurias, homocystinuria, disorders of leucine metabolism, glutaric acidemia type I, renal disease, and other diseases. The Phenylketonuria (PKU) market was the largest segment of the Medical Foods for Inborn Errors of Metabolism market segmented by diseases, accounting for 37.27% or $1.14 billion of the total in 2024. Going forward, the Phenylketonuria (PKU) segment is expected to be the fastest growing segment in the Medical Foods for Inborn Errors of Metabolism market segmented by diseases, at a CAGR of 13.99% during 2024-2029. The Medical Foods for Inborn Errors of Metabolism market is segmented by age group into infants, weaning, adolescents, and adults. The infants market was the largest segment of the Medical Foods for Inborn Errors of Metabolism market segmented by age group, accounting for 42.06% or $1.29 billion of the total in 2024. Going forward, the weaning segment is expected to be the fastest growing segment in the Medical Foods for Inborn Errors of Metabolism market segmented by age group, at a CAGR of 13.61% during 2024-2029. North America was the largest region in the Medical Foods for Inborn Errors of Metabolism market, accounting for 50.02% or $1.53 billion of the total in 2024. It was followed by Asia Pacific, Western Europe, and then the other regions. Going forward, the fastest-growing regions in the Medical Foods for Inborn Errors of Metabolism market will be Asia Pacific and Middle East where growth will be at CAGRs of 14.40% and 13.73% respectively. These will be followed by Africa and South America where the markets are expected to grow at CAGRs of 13.10% and 12.76% Attributes: Report Attribute Details No. of Pages 318 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $3.07 Billion Forecasted Market Value (USD) by 2034 $9.48 Billion Compound Annual Growth Rate 11.9% Regions Covered Global Some of the major companies featured in this Medical Foods for Inborn Errors of Metabolism market report include: Fresenius Kabi Nestle S.A. Abbott Laboratories Inc. Mount Sinai Health System Inc. Danone SA Ajinomoto Co. Inc. Reckitt Benckiser Group plc (Mead Johnson & Company, LLC) Galen Limited BC Children's Hospital Metagenics Inc. Institute of Liver and Biliary Sciences (ILBS) Primus Pharmaceuticals Inc. Medifood Vitaflo PhenylAde Nutricia Alticor Inc. USANA Health Sciences Alltech Archer-Daniels-Midland Co. Ancient Nutrition Amwell NutriScience Innovations, LLC Merck Sharp & Dohme Bristol Myers Squibb BIOVECTRA Factor Jnana Therapeutics Inc. Ningxia Eppen Solace Nutrition Piam Farmaceutici S.P.A. Sabinsa Corporation Galen Pharma Centogene NV Evonik Industries Herbalife Nutrition Nutramax Laboratories Centrum For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Medical Foods for Inborn Errors of Metabolism Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
